Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Lauren A. Byers, MD
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Luis Paz-Ares, MD, PhD
Real-World Ready: Practical Tips for Community Oncologists
Joshua Richter, MD
Sagar Lonial, MD, FACP
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
Noopur Raje, MD
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Data Dive: Clinical Evidence Behind CELMoDs
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
Maria Fleseriu, MD, FACE
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
John M. Kirkwood, MD
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD
Elizabeth R. Plimack, MD, MS, FASCO
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.